Dementia and Alzheimer Disease

In a recent analysis, BrainCheck Access showed a high degree of alignment with the Montreal Cognitive Assessment in differentiating normal cognition, mild cognitive impairment, and dementia.

The Delphi-MD platform is designed for nerve stimulation in diagnostic applications, offering clinicians a tool to support objective and personalized treatment approaches in brain health.

The ACCORD-2 trial demonstrated a significant reduction in overall worsening compared to placebo, while the ADVANCE-2 trial showed numerically greater improvements without reaching statistical significance.

Results from Vigil Neuroscience’s ongoing phase 1 trial of VG-3927 in healthy volunteers supported the continued development of the therapy as a potential once-daily oral treatment for Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on vascular dementia.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched expert-led video series that appeared on the website in 2024.

As part of NeurologyLive®'s Year in Review, we've compiled the most-listened episodes of our biweekly podcast, Mind Moments®.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched interview clips that appeared on the website in 2024.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news stories in Alzheimer disease and dementia in 2024.

Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2024, with insights from Daniel Ontaneda, MD, PhD; Ian Kremer; Andy Berkowski, MD, PhD; Sameea Husain-Wilson, DO; Jonathan Parker, MD, PhD; and Lawrence Robinson, MD. [LISTEN TIME: 25 minutes]

As part of NeurologyLive®'s Year in Review, we've compiled the top coverage stories from 2024 across a variety of different neurological conferences the team either attended or covered virtually.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2024.

The complement system is critical in immune defense and tissue homeostasis, but its dysregulation can contribute to autoimmune neurological disorders and neurodegenerative diseases like Alzheimer, ALS, and multiple sclerosis.

As new treatments become available, it may be essential to achieve a timely and accurate diagnosis to enable patients and their family to make informed decisions and retain the greatest level of autonomy.

Here's some of what is coming soon to NeurologyLive® this week.

The investigational therapy was safe, well-tolerated, and showed promising improvements in cognitive measures among patients with dementia with Lewy bodies.

The cumulative incidence of dementia was higher in people with OSA, particularly for women, across different age groups.

The chief executive officer and cofounder of Amprion provided clinical insight on the novelty behind the company’s synuclein seed amplification assay and how it may better differentiate synucleinopathies diseases like MSA. [WATCH TIME: 8 minutes]

Most recently reported topline data from the RewinD-LB phase 2b trial in patients with dementia with Lewy bodies showed that neflamapimod failed to meet its primary end point and secondary end points.

Here's some of what is coming soon to NeurologyLive® this week.

Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.

Factors like education level, hypertension, diabetes, and depression did not significantly predict epilepsy risk in patients with dementia.